My Profile

Search abstracts

Lewis Sheiner


2019
Stockholm, Sweden



2018
Montreux, Switzerland

2017
Budapest, Hungary

2016
Lisboa, Portugal

2015
Hersonissos, Crete, Greece

2014
Alicante, Spain

2013
Glasgow, Scotland

2012
Venice, Italy

2011
Athens, Greece

2010
Berlin, Germany

2009
St. Petersburg, Russia

2008
Marseille, France

2007
København, Denmark

2006
Brugge/Bruges, Belgium

2005
Pamplona, Spain

2004
Uppsala, Sweden

2003
Verona, Italy

2002
Paris, France

2001
Basel, Switzerland

2000
Salamanca, Spain

1999
Saintes, France

1998
Wuppertal, Germany

1997
Glasgow, Scotland

1996
Sandwich, UK

1995
Frankfurt, Germany

1994
Greenford, UK

1993
Paris, France

1992
Basel, Switzerland



Printable version

PAGE. Abstracts of the Annual Meeting of the Population Approach Group in Europe.
ISSN 1871-6032

Reference:
PAGE 28 (2019) Abstr 8862 [www.page-meeting.org/?abstract=8862]


Oral: Drug/Disease modelling


B-11 Chiara Nicolò Machine learning combined to mechanistic modeling of differential effects of neoadjuvant sunitinib on primary tumor and metastatic growth

C. Nicolò (1,2), M. Mastri (3), J. ML Ebos (3,4), S. Benzekry (1,2)

(1) MONC team, Inria Bordeaux Sud-Ouest, Talence, France, (2) Institut de Mathématiques de Bordeaux, Bordeaux University, Talence, France, (3) Department of Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA, (4) Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

Introduction:

Despite proven clinical action of angiogenic inhibitors [1], recent experimental evidence also suggests differential effects of these drugs on primary and secondary tumors [2]–[4]. In this work we extended our previous mechanistic model [5] to describe the effect of neoadjuvant sunitinib therapy in an ortho-surgical mouse model of spontaneous metastatic breast cancer. Model development was guided by a large experimental data set of 104 mice treated with multiple scheduling strategies. The experimental data comprised longitudinal measurements of primary tumor (PT) size and metastatic burden (MB), as well as survival data and pre-surgical biomarkers (circulating tumor cells (CTCs) and myeloid-derived suppressor cells (MDSCs) counts and proliferation and endothelial immunohistochemical markers).

Objectives:

  • Understand the differential effects of Suntinib on primary tumor and metastatic growth
  • Establish a minimal kinetics-pharmacodynamics (K-PD) model of neoadjuvat suntinib therapy
  • Assess the predictive power of biomarkers on the model parameters

Methods:

We adapted a previously established mathematical model [5] to include the effect of neoadjuvant sunitinib therapy by assuming that the drug reduces the primary tumor growth rate by a term proportional to its concentration. As no pharmacokinetic data were collected in our study, we used a K-PD approach (one compartment model with elimination rate from the literature [6]).

PT and MB data were fitted simultaneously for vehicle and sunitinib-treated animals using a nonlinear-mixed effects modeling approach [7]. Maximum likelihood estimates of the population parameters were obtained using the Stochastic Approximation of Expectation-Maximization (SAEM) algorithm implemented in the nlmefitsa Matlab function [8].

Effects of covariates on the model parameters were assessed using linear regression and a number of machine learning regression techniques (artificial neural networks, support vector machines, random forest models) [9] using the train function of the R caret package [10], [11].

Survival times were analyzed using the Monolix software [12]. A log-logistic distribution was used. We utilized the COSSAC (Conditional Sampling for Stepwise Approach based on Correlation tests) covariate selection algorithm for automatic building of the covariate model [13].

Results:

We used parameter values estimated from a previous study on control groups [5] to generate model predictions under the assumptions of effect (A) or no effect of therapy on metastatic growth (B). Population distributions obtained under the hypothesis A failed to describe the data, whereas simulations under hypothesis B reproduced the behavior of the experimental data notably well. This was observed in all the treated groups and suggested rejection of the assumption A, with B being a valid possible alternative.

Based on these results, the K-PD model we developed considered that the antiangiogenic agent affects only primary tumor growth. The calibrated K-PD model was able to describe both the structural dynamics and inter-subject variability of the experimental data in both vehicle and treated animals. The model parameters were identified with good precision (relative standard error ≤ 17%) thanks to the large number of animals (n=104). Confirming previous results [5], interanimal variability was mainly characterized by a model parameter μ expressing the metastatic potential of the tumor, which was also found to be significant for predicting survival. However, the biomarkers included in all tested machine learning algorithms demonstrated only limited predictive power on the mathematical parameters (R2 = 0.13 – 0.2, best relative error on  9.83  10.70 %).

Conclusions:

We developed a K-PD model for describing the effects of neoadjuvant antiangiogenic treatment on primary and metastatic growth dynamics. Analysis of a large data set revealed a highly heterogeneous population in terms of the metastatic potential parameter μ. Identifying biological predictors of μ would be of critical clinical interest by providing more individualized. According to our analysis of the biomarkers as covariates in the model, expression of Ki67 and CD31 in the primary tumor, and pre-surgical CTC and MDSC levels are not significant predictors of metastatic potential and survival. Although likely to depend on the animal model of cancer, these results highlight the need to investigate other molecular and cellular markers.



References:
[1] G. C. Jayson, R. Kerbel, L. M. Ellis, and A. L. Harris, ‘Antiangiogenic therapy in oncology: current status and future directions’, The Lancet, vol. 388, no. 10043, pp. 518–529, Jul. 2016.
[2] J. M. L. Ebos, C. R. Lee, W. Cruz-Munoz, G. A. Bjarnason, J. G. Christensen, and R. S. Kerbel, ‘Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis’, Cancer Cell, vol. 15, no. 3, pp. 232–239, Mar. 2009.
[3] M. Pàez-Ribeset al., ‘Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis’, Cancer Cell, vol. 15, no. 3, pp. 220–231, Mar. 2009.
[4] J. M. L. Ebos et al., ‘Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy’, EMBO Mol Med, vol. 6, no. 12, pp. 1561–1576, Dec. 2014.
[5] S. Benzekry, A. Tracz, M. Mastri, R. Corbelli, D. Barbolosi, and J. M. Ebos, ‘Modeling spontaneous metastasis following surgery: an in vivo-in silico approach’, Cancer Res, vol. 76, no. 3, pp. 535–547, Feb. 2016.
[6] Q. Zhou and J. M. Gallo, ‘Quantification of sunitinib in mouse plasma, brain tumor and normal brain using liquid chromatography-electrospray ionization-tandem mass spectrometry and pharmacokinetic application’, J Pharm Biomed Anal, vol. 51, no. 4, p. 958, Mar. 2010.
[7] M. Lavielle, Mixed Effects Models for the Population Approach: Models, Tasks, Methods and Tools. 2014.
[8] Matlab with statistics and optimization toolboxes. The Mathworks Inc.; 2015
[9] M. Kuhn and K. Johnson, Applied predictive modeling, vol. 26. Springer, 2013.
[10] Max Kuhn. Contributions from Jed Wing, Steve Weston, Andre Williams, Chris Keefer, Allan Engelhardt, Tony Cooper, Zachary  Mayer, Brenton Kenkel, the R Core Team, Michael Benesty, Reynald Lescarbeau, Andrew Ziem, Luca Scrucca, Yuan Tang, Can   Candan and Tyler Hunt. (2018). caret: Classification and Regression Training. R package version 6.0-80.   https://CRAN.R-project.org/package=caret. .
[11] R Core Team (2018). R: A language and environment for statistical computing. R Foundation for Statistical Computing,  Vienna, Austria. URL https://www.R-project.org/.
[12] Monolix version 2018R1. Antony, France: Lixoft SAS, 2018. http://lixoft.com/products/monolix/.
[13] Marc Lavielle and Jonathan Chauvin (2018). Rsmlx: R Speaks ‘Monolix’. R package version 1.1.0.  https://CRAN.R-project.org/package=Rsmlx.